Palopegteriparatide

Palopegteriparatide, sold under the brand name Yorvipath, is a hormone replacement therapy used for the treatment of chronic hypoparathyroidism. It is a transiently pegylated parathyroid hormone.

Medical uses
Yorvipath indicated for the treatment of adults with chronic hypoparathyroidism.

Legal status
In September 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Yorvipath, intended for the treatment of chronic hypoparathyroidism in adults. The applicant for this medicinal product is Ascendis Pharma Bone Diseases A/S. Palopegteriparatide was approved for medical use in the European Union in November 2023.

Palopegteriparatide was granted an orphan drug designation by the US Food and Drug Administration (FDA) in 2018, and by the EMA in 2020.

Brand names
Palopegteriparatide is the international nonproprietary name.

Palopegteriparatide is sold under the brand name Yorvipath.